HemaSphere (Jun 2022)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

  • A. DeZern,
  • G. Marconi,
  • D. Deeren,
  • M. Diez Campelo,
  • M. Lübbert,
  • P. Krishnamurthy,
  • Z. Nagy,
  • G. Basak,
  • A. Jonášová,
  • E. Morozova,
  • K. Geissler,
  • Y. Ofran,
  • H. Kelley,
  • A. Volkert,
  • K. Baker,
  • Q. Kang-Fortner,
  • G. Hodgson,
  • C. Madigan,
  • D. A. Roth,
  • M. Kelly,
  • P. Fenaux

DOI
https://doi.org/10.1097/01.HS9.0000850536.85159.f8
Journal volume & issue
Vol. 6
pp. 1800 – 1801

Abstract

Read online

No abstracts available.